Expert faculty will discuss the most recent and talked about articles published in the past year.
Clinicians often find themselves navigating a gauntlet of choices when recommending over the counter (OTC) medications for an acute viral respiratory illness. Decisions about NSAIDs, acetaminophen and aspirin to manage pain, inflammation and fever may now be more complicated given the COVID-19 pandemic. This session will dispel common misunderstandings about pain and fever reducing medications, with a focused discussion on some of the recent misconceptions surrounding NSAID use in relation to COVID-19. Faculty will present appropriate applications of NSAIDs and acetaminophen, based on current literature and evidence-based data.
This session will use four case presentations as a guide to review cancer and chronic disease differences and prevalence by race/ethnicity. Specific differences in diseases seen in Asian Americans and African Americans will be highlighted. Tobacco use and trends in different populations will also be emphasized.
In the last year, two new diseases have emerged with significant and lasting impact on the lung: E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and COVID-19 pneumonia. This session will address new information and challenges related to both diseases. Vaping has increased in popularity, especially among youth, and in late 2019, EVALI was first described. While the outbreak has subsided, recognition of the symptoms, association with marijuana use, and radiographic findings of EVALI remain important. Further, providing tobacco and marijuana cessation guidance remains critical. The COVID-19 pandemic, caused by SARS-Cov2 virus, has burdened healthcare workers and scientists across the globe. COVID-19, often associated with severe pneumonia and systemic illness, has resulted in significant morbidity and mortality in the US and we can continue to learn and discover its full impact. Additionally, COVID-19 has unmasked major health disparities in our healthcare system that we must address.
My COVID Experience and Renal & GI Disease Differences: Patient-Centered Clinical Care for African Americans
Episode 6: Bridging the Gap: Conversations with Dr. Hall
In this session, Dr. Hall will discuss his recent experience as a patient with COVID-19, which led to his admission to the ICU. Following this discussion, Dr. Hall will provide an overview of the health disparities related to kidney and gastrointestinal diseases in African Americans. Next, he will review the significantly increased incidence of renal disease and discuss some of the causes, including a genetic link. Infectious hepatitis demographics and other gastrointestinal disease differences will also be reviewed. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 1/19/2021 and they are subject to change as new information is published.
Episode 1: Bridging the Gap: Conversations with Dr. Hall
In this session, Dr. Gregory Hall will provide a foundation of information including current statistics and demographics of African Americans’ health. He will review trust and bias issues as well as their origins in the history of healthcare of African Americans. Finally, he will provide some examples of important differences in the clinical care of African Americans as he sets the stage for more detailed discussion in future sessions of this monthly webcast. Dr. Hall is a Primary Care Physician and an expert in Black American Health and Healthcare. He is the former chair of the Ohio Commission on Minority Health, Director of the National Center for African American Health, Research, Education and Policy at Cleveland State University, and Author of “Patient-Centered Clinical Care for African Americans: A Concise, Evidence-Based Guide to Important Differences and Better Outcomes”. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 07/14/2021 and they are subject to change as new information is published.
With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the use of the COVID-19 vaccine in two important patient populations: adolescents and pregnant women. You’ll also hear the latest guidance on when to wear a mask.
Coronary artery calcium can be a valuable tool to measure cardiovascular risk and to inform the treatment of hyperlipidemia in appropriately selected individuals. Join Dr. Ty Gluckman as he discusses the history, predictive value, and most effective use of coronary artery calcium.
In the twenty-first episode of Pri-Med’s web series on COVID-19, faculty will provide some insight into a newly relevant COVID-19 treatment; monoclonal antibodies. Current events have shown a light on monoclonal antibodies and faculty will distinguish this treatment from convalescent plasma and hyperimmune globulin, as well as explain how it is made and might work against COVID-19. The second topic of this webcast will focus on mental health its status as we approach a year into a pandemic. Faculty will also discuss some recent data on the impact that mindfulness programs might have as an intervention to improve mental health.
Hypercholesteremia is highly prevalent in the U.S. and strongly associated with cardiovascular morbidity and mortality. Yet, only about 55% of U.S. adults appropriate for cholesterol lowering therapy are currently taking it. What do primary care providers need to know to improve the care of the many individuals with hypercholesterolemia that you see daily in clinical practice? Join Dr. Ty Gluckman for part 2 of this webcast series to find out.
Episode 9: Bridging the Gap: Conversations with Dr. Hall
Pulmonary diseases and sleep issues are yet two more areas of health inequity in the United States, with African Americans again shouldering much of the burden. See recent data that shed light on how health disparities in obstructive sleep apnea and poor sleep patterns in general have developed—the reasons may surprise you!—and how these conditions, if untreated, can lead to poor overall health and quality of life in this community.
After implementing current guideline-directed medical management, there is still urgency to address residual cardiovascular risk. Among the drivers of residual cardiovascular risk, inflammation has generated considerable interest, first based on preclinical and biomarker studies in humans. More recently, translation has inspired clinical trials in this domain. This presentation will consider inflammation as a process that links traditional and nontraditional risk factors to atherothrombotic events.